DMK Pharmaceuticals Corporation
DMKPQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -1,034.73% | -440.51% | -565.04% | -606.51% |
| EV / EBITDA | -0.08 | 0.45 | -0.04 | 0.04 |
| Quality | ||||
| ROIC | 20,463.87% | -115.47% | -233.51% | -71.46% |
| Gross Margin | -60.93% | -211.14% | -127.87% | 29.10% |
| Cash Conversion Ratio | 0.99 | 1.09 | 0.58 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.65% | -53.60% | -43.12% | 19.15% |
| Free Cash Flow Growth | 31.86% | -80.58% | 5.06% | 37.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.03 | 0.74 | 0.08 | 0.19 |
| Interest Coverage | 0.00 | -4,823.19 | -6,437.68 | -243.41 |
| Efficiency | ||||
| Inventory Turnover | 6.18 | 16.42 | 5.16 | 7.61 |
| Cash Conversion Cycle | -236.18 | 797.87 | -0.06 | -20.38 |